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Members of the heat shock protein 70 (HSP70) family play an important role in assisting pro-
tein folding, preventing protein aggregation and transport of proteins across membranes
under physiological conditions. Following environmental (i.e., irradiation, chemotherapy),
physiological (i.e., cell growth, differentiation), and pathophysiological (i.e., inflammation,
tumorigenesis) stress, the synthesis of heat shock proteins (HSPs) is highly up-regulated,
whereas protein synthesis in general is reduced. In contrast to normal cells, many tumor
entities including hepatocellular carcinoma (HCC) overexpress HSP70, the major-stress-
inducible member of the HSP70 family, present it on their cell surface and secrete it into
the extracellular milieu. Herein, the prognostic relevance of serum HSP70 levels in patients
with chronic hepatitis (CH; n=50), liver cirrhosis (LC; n=46), and HCC (n=47) was ana-
lyzed. Similar to other tumor entities, HSP70 is also present on the surface of primary HCC
cells. The staining intensity of intracellular HSP70 in HCC tissue is stronger compared to
control and cirrhotic liver sections. HSP70 serum levels in all HCC patients were signifi-
cantly higher compared to a control group without liver disease (n=40). No significant age-
and gender-related differences in HSP70 serum levels were observed in male and female
healthy human volunteers (n=86). Patients with CH (n=50) revealed significantly higher
HSP70 serum levels compared to the control group, however, these values were signifi-
cantly lower than those of HCC patients (n=47). Furthermore, a subgroup of patients with
LC who subsequently developed HCC (LC-HCC, n=13) revealed higher HSP70 serum lev-
els than patients with LC (n=46, p=0.05). These data indicate that serum HSP70 levels
are consecutively increased in patients with CH, LC and liver carcinomas and thus might
have a prognostic value.
Keywords: HCC, serum HSP70, prognostic biomarker, chronic hepatitis, inflammation, liver cirrhosis
INTRODUCTION
The incidence of hepatocellular carcinoma (HCC) is increasing
dramatically in the Western societies in the last years and HCC is
the third leading cause of cancer-related deaths (1). Heavy alcohol
intake, tobacco, vinyl chloride, and aflatoxin-B1 toxin can initi-
ate HCC in humans. Apart from toxins, HCC can also arise from
a dysregulated expression of small non-coding microRNAs (i.e.,
miR-122), diabetes, non-alcoholic fatty liver disease, hemochro-
matosis, liver cirrhosis (LC), and chronic hepatitis (CH) B/C viral
infections. The exact molecular mechanisms that promote the
transition of diseased liver cells into neoplastic lesions remain to
be unsolved. The production of pro-inflammatory cytokines and
chemokines, which induces a chronic inflammation in the liver
are discussed to increase the risk for a malignant transformation
(2–4). These data indicate that a multitude of different parameters
including toxins, diseases, and the microenvironment of the host
can play a role in the development of HCC (5).
At present, the histological evaluation of liver biopsies using
the Edmondson–Steiner classification is the gold standard for
the grading of HCC. For patients suffering from HCC with an
underlying LC the Barcelona Clinic Liver Cancer group (BCLC)
classification is used to describe the tumor volume, the grade of
cirrhosis and the patient performance status. Apart from morpho-
logical inspections, antibodies directed against cyclase-associated
protein 2 (CAP2) or glypican-3 are applied in immunohistochem-
istry to distinguish different tumor stages and to separate malig-
nant from non-malignant lesions (6). Several other tumor bio-
markers, such as p53, mammalian target of rapamycin (mTOR),
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c-MET, insulin-like growth factor 1 receptor (IGF-1R), histone
MacroH2A1 (7), and heat shock proteins (HSP) (8) including
HSP70 are frequently up-regulated in tumor biopsies of HCC
patients. However, the prognostic value of any of these markers
alone is limited since its reliability can be impacted by gender and
disease related parameters. Elevated mRNA levels of p53 are not
only detected in male tumor patients with undifferentiated tumor
stages but also in patients with cirrhosis (5). Similar results were
found for an increased expression of mTOR that is also associated
with other malignancies (5).
A major disadvantage of biopsy-based biomarkers is their lim-
ited availability and the risk to develop infections by the surgical
intervention. Soluble, blood-derived biomarkers are superior to
biopsies since they are easily accessible and can be taken repeat-
edly by using minimal invasive methods. In the present study, we
aim to evaluate the prognostic significance of the major stress-
inducible HSP70 in the serum of patients as a potential biomarker
to distinguish patients with chronic inflammation (i.e., patients
with CH) and LC from patients with HCC.
Members of the HSP70 family play a pivotal role in assist-
ing protein folding, preventing protein aggregation and transport
of proteins across membranes under physiological conditions.
Following environmental (i.e., irradiation, chemotherapy, oxy-
gen radicals), physiological (i.e., cell growth, differentiation), and
pathophysiological (i.e., inflammation, tumor growth) stress, the
synthesis of HSPs in general, but especially that of HSP70, is highly
up-regulated, whereas that of other proteins is down-regulated. In
contrast to normal cells, tumor cells frequently overexpress HSP70
in the cytosol (9), present it on their plasma membrane (10) and
can actively secrete it in lipid vesicles such as exosomes (8, 11).
The vesicular export of HSP70 in extracellular fluids was reported
to stimulate effector mechanisms of the immune system (11, 12).
Immunohistochemical analysis of tumor biopsies suggests that
HSP70 in combination with other markers such as glutamine syn-
thetase could serve as a putative diagnostic marker in HCC (6).
Apart from HCC (13), an elevated expression of HSP70 was also
found in patients with early-stage pancreatic cancer (14). High
cytosolic HSP70 levels can promote tumor growth, prevent apop-
totic cell death and thus are often associated resistance to therapy
and poor prognosis in many different cancer types (8).
MATERIALS AND METHODS
HEALTHY HUMAN VOLUNTEERS AND PATIENTS
Eighty-six male and female healthy human volunteers (HEALTHY,
n= 86) at different ages were enrolled into the study as well
as patients suffering from CH (CH, n= 50), LC (n= 46), HCC
(HCC, n= 47), and patients without a liver disease (n= 40)
(Table 2). Approval was obtained by the Ethics Committees of
the University Palermo, Italy, and the Klinikum rechts der Isar,
Technische Universität München, Germany. All procedures were
in accordance with the ethical standards of the responsible insti-
tutional and national committees on human experimentation and
with the Helsinki Declaration of 1975 as revised in 2008.
Serum samples were collected from human patients with and
without liver disease and healthy human volunteers at different
ages. Blood samples of patients were taken after overnight fasting.
After centrifugation (10 min, 750× g, room temperature), part of
the serum was used to assay the main parameters of liver function
by routine methods. Serum aliquots of 100–500µl were stored at
−80°C for the measurements of HSP70. Sera were thawed only
once for testing. Serological testing for anti-HCV was performed
using a commercial third-generation enzyme-linked immunosor-
bent assay (ELISA) (Ortho Diagnostic System, Raritan, NJ, USA),
in accordance with the manufacturer’s instructions. Serum lev-
els of HCV-RNA were evaluated qualitatively by the Amplicor
HCV test, version 2.0 (Roche Diagnostics, Basel, Switzerland) and
quantitatively at baseline by the Cobas Monitor Test, version 2.0
(Roche Diagnostics). Markers of HBV were tested using the Abbott
radioimmunoassay kit (Abbott Laboratories,Abott Park, IL, USA).
TUMOR BIOPSIES
Liver biopsy samples were obtained percutaneously according to
the Menghini technique using needles of 1.0± 1.2 mm diameter
(Surecut, Hospital Service, Rome, Italy). In some cases, HCC was
diagnosed using a thin needle (20 Gage, Surecut) under ultra-
scan control, using a Toshiba SSA 240A apparatus with a 3.5-MHz
probe. Tissues from HCC and adjacent liver were obtained from
patients undergoing surgical resection. Histologically normal liver
tissue was obtained from patients during surgery for cholelithiasis.
Written informed consent was obtained in all cases; the protocol
was approved by the local Ethics Committee 1(see above). Biopsies
in the size range of a few mm were taken during tumor excision.
FLOW CYTOMETRY
Single cells from freshly isolated tumor biopsies were prepared by
mechanical disruption, as described previously (15). 1× 105 cells
were washed once with 10% FCS in phosphate buffered saline
(PBS) and incubated with a FITC-conjugated mouse monoclonal
antibody specific for membrane-bound HSP70 (cmHSP70.1,
IgG1, multimmune GmbH, Munich, Germany) (16) or a FITC-
labeled isotype-matched IgG1 negative control antibody (345815,
BD Biosciences, Franklin Lakes, NJ, USA) on ice in the dark for
30 min. After washing, propidium iodide was added and viable
cells were immediately analyzed on a FACSCalibur flow cytometer
(BD Biosciences). The percentage of cells stained with an isotype-
matched control antibody was subtracted from the percentage of
cmHSP70.1 antibody positive cells.
IMMUNOHISTOCHEMICAL STAINING
Immunohistochemical investigation was performed on specimens
fixed in formalin and embedded in paraffin. Four micrometer-
thick sections were cut, dewaxed, and hydrated, heated in a
microwave oven (three to four cycles of 5 min each) in 10 mM
citrate buffer (pH 6.0), then washed twice with PBS for 5 min.
All sections were incubated in 3% hydrogen peroxide (v/v) in
methanol for 5 min. Immunohistochemistry was performed with
the Streptavidin–biotin complex (StreptABC) using rabbit poly-
clonal antibody against HSP70 (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) at a dilution of 1:200 for 2 h at 37°C.
Sections were then incubated for 30 min at RT with biotinylated
anti-rabbit immunoglobulin diluted in PBS, with StreptABC for
30 min at RT, and the color was developed with 3-amino-9-ethyl-
carbazole (AEC) (Dako, Copenhagen, Denmark) for 5–10 min at
RT, and counterstained with Mayer hematoxylin for 3 min. Results
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FIGURE 1 | Representative images of a high (left) and low (right)
HSP70 membrane expression on primary HCC cells. Single cell
suspensions from freshly isolated HCC biopsies derived from two different
patients were incubated with FITC-conjugated mouse monoclonal antibody
cmHSP70.1 that recognizes the membrane-bound form of HSP70 on the
surface of tumor cells. The white histogram represents the HSP70
membrane staining of the tumor cells and the gray histogram the staining
with a negative control FITC-conjugated isotype-matched control antibody.
The percentage of HSP70 membrane-positive cells was corrected by
subtraction of the isotype control.
were assessed semiquantitatively in blind by three expert patholo-
gists and by counting the proportion of positively stained cells in
10 random high power fields at a 10 and 40×magnification.
ELISA ASSAYS
Total HSP70 levels in serum samples of humans were measured
using an HSP70 immunoassay (Duoset, DYC1663, R&D Sys-
tems, Minneapolis, MN, USA), according to the manufacturer’s
instructions with modified buffers. The ELISA is designed to
detect inducible human HSP70. All serum samples were tested
in three independent ELISA experiments in duplicates. HSP70
was detected by incubation with HRP-conjugated anti-human
Ig followed by HRP-substrate staining (DY999, R&D Systems,
Minneapolis, MN, USA). Signals were determined by measuring
the absorption at 450 nm in a standard ELISA reader (BioTek,
Winooski, VT, USA) with a correction wavelength set to 540 nm.
STATISTICAL ANALYSIS
Statistical analysis was performed using SigmaPlot software deliv-
ered by Systat Software, Inc. (San Jose, CA, USA). Results of the
levels of soluble HSP70 are presented as standard box plots with
boundaries indicating the 25th and the 75th percentile. The line
inside boxes indicates the median and the whiskers indicate the
10th and 90th percentile, respectively. All outliers are shown. For
comparison between groups of data the Student’s t -test or the
Mann–Whitney Rank Sum Test were used to evaluate differences.
p-Values <0.05 are considered to be statistically significant.
RESULTS
HSP70 MEMBRANE PHENOTYPE ON BIOPSIES OF PATIENTS WITH HCC
Freshly isolated, non-fixed biopsies of patients with HCC were
minced and filtered through a sterile mesh to obtain single cell
suspensions of the tumor. Directly after washing tumor cells
were centrifuged and incubated with FITC-conjugated mouse
monoclonal antibody (mAb) cmHSP70.1 that recognizes the
membrane-bound form of HSP70 on the surface of viable tumor
Table 1 | HSP70 membrane status in single cell suspensions of HCC
tissue obtained from tumor patients.
Patient no. HSP70+ Mean fluorescence HSP70
cells (%) intensity (MFI) phenotype
1 62 429 +
2 95 1923 +
3 33 158 +
4 12 27 −
5 14 37 −
cells with an intact membrane (Figure 1, white histograms). As
a negative control, a FITC-conjugated isotype-matched control
antibody was used (Figure 1, gray histograms). The percentage
of HSP70 positively stained cells was corrected according to the
results from the staining with an isotype-matched control anti-
body. The histograms depicted in Figure 1 show a typical result
of a high (62%) and low (14%) membrane HSP70 positive tumor
biopsy. Previous studies with biopsies of normal tissues revealed
that a sample is considered as HSP70 membrane-positive if more
than 20% of the cells are stained positively with the cmHSP70.1
mAb (17). With respect to this threshold, three out of five selected
HCC patient samples were HSP70 membrane-positive (Table 1).
This finding is in line with results derived from other human
tumor entities (n= 978), showing that more than 50% of all
tested tumor samples were found to be HSP70 membrane-positive
(10, 15).
REPRESENTATIVE IMMUNOHISTOCHEMICAL ANALYSIS OF THE HSP70
PROTEIN CONTENT IN LIVER SECTIONS OF HUMAN VOLUNTEERS
WITHOUT LIVER DISEASE (CTRL) AND HCC PATIENTS WITH
UNDERLYING LC
The patient cohort consists of 183 subjects that could be divided
into four groups (Table 2). Group 1 was composed of 40
patients (CTRL) without liver disease derived from the Biomedical
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Table 2 | Clinical and pathological features of control patients without liver diseases (CTRL) and patients with chronic hepatitis (CH), liver
cirrhosis (LC), and hepatocellular carcinoma (HCC); data are expressed as the median (range).
Characteristics Group 1 CTRL Group 2 CH Group 3 LC Group 4 HCC
Number (n) 40 50 46 47
Gender (M/F) 36/4 30/20 24/22 27/20
Age (years) 44 (23–63) 52.5 (25–85) 66.5 (30–86) 73 (45–87)
Albumin (g/dl) 4.7 (3.47–5.01) 4.66 (4.0–4.9) 3.4 (2.0–4.5) 1.03 (0.24–5.56)
Bilirubin (mg/dl) total 0.72 (0.52–1.0) 0.75 (0.34–1.1) 1.27 (0.15–5.89) 1.03 (0.24–5.56)
Aspartate amino-transferase (IU/ml) 18.7 (12.0–26.1) 55 (25.0–173.0) 70 (19.0–377.0) 56 (12.0–204.0)
Alanine amino-transferase (IU/ml) 16.2 (11.5–22.02) 85 (31.0–251.0) 57 (12.0–221.0) 45 (12.0–230.0)
International normalized ratio (INR) 0.92 (0.86–1.01) 0.97 (0.91–1.07) 1.24 (1.06–1.73) 1.06 (0.82–1.75)
HBs Ag – 2 4 3
HCV Ab – 38 32 34
Alcoholism – None 3 5
Cryptogenic – 10 7 4
Dysmetabolic – None None 1
BCLC
A – – – 21
B – – – 9
C – – – 8
D – – – 5
E – – – 4
CHILD-PUGH
A – – 26 –
B – – 16 –
C – – 4 –
BCLC, Barcelona Clinic Liver Cancer group; HBs Ag, anti-hepatitis B surface antigen; HCV Ab, anti-hepatitis antibody.
Department of Internal Medicine and Specialties, University of
Palermo, Palermo, Italy. Liver disease was excluded on the basis of
anamnestic, biochemical, and instrumental data. In this group, no
case of neoplastic disease was detected within a follow-up period of
at least 6 months. Group 2 included 50 patients with CH infections
and Group 3 included 46 patients with LC. Diagnosis was made on
the basis of liver biopsies and unequivocal biochemical and instru-
mental data. The absence of neoplasia had been verified during a
post-study follow-up period of at least 6 months. Finally, group 4
included 47 patients with HCC. Diagnosis was based on histology,
cytology, multiple concordant imaging techniques [ultrasound,
basal and lipiodol computed tomography (CT), selective angiog-
raphy], and biochemical assays (serum levels of AFP>200 ng/ml).
Some of the patients were known as liver cirrhotics and had been
enrolled in a prospective study for HCC screening.
Representative immunohistochemical images were taken from
sections of liver biopsies of human patients without liver dis-
ease (CTRL) and a patient who was diagnosed with HCC and
LC (Figure 2A). The HSP70 staining intensity was stronger in the
HCC tissue compared to that of the control liver (CTRL) and to
the cirrhotic part (LC) of the patient biopsy. These data indicate
that the intracellular HSP70 content is higher in the cancerous
compared to the cirrhotic liver tissue. A comparison of four dif-
ferent LC-HCC patients revealed different staining intensities in
the HCC and LC regions and between the different patient sections
(Figure 2B).
HSP70 PROTEIN LEVELS IN THE SERUM OF HUMAN VOLUNTEERS
(HEALTHY), PATIENTS WITHOUT LIVER DISEASE (CTRL), AND PATIENTS
WITH CHRONIC HEPATITIS, LIVER CIRRHOSIS, AND HEPATOCELLULAR
CARCINOMAS
The soluble HSP70 levels were determined in the serum of 86
male (54) and female (32) healthy human volunteers at different
ages. Irrespectively of the age and gender, the HSP70 serum lev-
els did not differ significantly in the healthy human volunteers
(HEALTHY) (Figure 3A). A comparison of the HSP70 levels in
patients without liver disease (CTRL, n= 40, 2.7± 0.9 ng/ml) and
healthy human volunteers (HEALTHY, n= 86, 2.3± 0.8 ng/ml)
also revealed no significant differences (Figure 3B). In contrast,
the HSP70 serum levels of patients with liver diseases such as
CH, LC, and HCC differed significantly from that of healthy
human volunteers and patients without liver disease. The highest
serum HSP70 levels in patients were found in HCC (HCC, n= 47,
6.5± 3.1 ng/ml) and LC patients (LC, n= 46, 6.6± 5.2 ng/ml).
The lowest HSP70 levels were found in patients with CH (n= 50,
3.9± 2.4 ng/ml). These values were significantly lower than that
of HCC and LC patients (Figure 3B).
In order to evaluate whether the HSP70 serum levels could pre-
dict the risk to develop HCC a subgroup analysis was performed.
As shown in Figure 3C, a small subgroup of HCC patients with
underlying LC revealed higher HSP70 serum levels (LC-HCC,
n= 13, 7.3± 2.2 ng/ml) than the overall group of patients with
LC (6.6± 5.2 ng/ml) with unknown HCC status. However, due to
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FIGURE 2 | (A) Representative immunohistochemical images of the
HSP70 staining in control liver tissue (CTRL) and in the tissue of a patient
with hepatocellular carcinoma (HCC) with an underlying liver cirrhosis
(LC). The HSP70 staining intensity was stronger in HCC tissue compared
to that of control liver tissue (CTRL) and in areas with liver cirrhosis (LC);
left panel 10× magnification, right panel 40× magnification.
(B) Semiquantitative analysis of the HSP70 staining intensity in sections
of LC-HCC patients (n= 4) at a 10× magnification. The HSP70 staining
intensity in the HCC regions ranged from very strong (+++), via
intermediate (++) to strong (+); in the LC regions the staining intensity
ranged between strong (+), weak (±), and very weak (−) in the four
different sections.
the low number of patients (n= 13) only a trend (p= 0.05) was
determined.
DISCUSSION
Biomarkers are used to detect tumors, monitor tumor growth,
and to assess the effectiveness of anti-cancer therapies (18). A
major disadvantage of biopsy-based markers is the risk for devel-
oping infections caused by the invasive intervention. Since blood
samples can be taken by minimal invasive methods from patients
before, during, and after therapy this method is superior for tumor
detection and for monitoring the clinical outcome. In this study,
soluble HSP70 was examined for its potential prognostic signifi-
cance to serve as a blood-derived biomarker to detect HCC and
to distinguish HCC from other liver diseases such as CH and LC.
Previous studies of our group already have shown that HSP70
membrane-positive tumors actively secrete HSP70 into the extra-
cellular milieu in cell cultures (11). This result could be confirmed
in tumor bearing mice (19) and in patients with squamous cell
carcinomas of the head and neck (Ms submitted). Since the avail-
ability of tumor biopsy material is limited during the course of
disease, we addressed the question whether serum HSP70 levels
could reflect the HSP70 membrane status of the tumor cells also
in HCC patients. Comparative analysis revealed that an increased
intracellular HSP70 staining intensity of HCC cells in sections was
associated with increased serum HSP70 levels in a selected group
of patients who suffered from HCC and LC (data not shown). In
a group of patients with HCC only, the cytosolic HSP70 levels did
not correlate with soluble HSP70 levels. This is in line with the
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findings of Kang et al. (5) who showed no correlation of cytosolic
HSP70 levels with prognosis of HCC after resection. The excellent
accessibility of serum biomarkers allows repeated testing during
the course of a disease and the monitoring of clinical outcome.
Serum HSP70 levels have been discussed to provide a useful bio-
marker for testing the efficacy of an Hsp90 inhibitor-based tumor
therapy that is known to induce the expression of HSP70 (20).
It has been reported that HSP70 can be actively released by
viable tumor cells with an intact cell membrane (21). In this study,
we could show that patients with HCC exhibited significantly
higher HSP70 serum levels compared to patients with hepatic viral
infections (Figure 3). These findings might provide a hint that the
largest proportion of soluble HSP70 in the serum is produced by
viable tumor cells that actively secrete HSP70 in lipid vesicles and
not by necrosis of inflamed liver tissue. Together with the find-
ing that serum HSP70 levels correlate with the volume of viable
tumor cells in mice (19), we hypothesize that soluble HSP70 levels
might be useful to evaluate the mass of vital tumor cells in human
patients before and after therapeutic intervention.
Since membrane HSP70 is frequently present on a broad vari-
ety of different tumor entities such as colorectal, lung, pancreatic,
and prostate cancer patients (14, 20, 22, 23) and since membrane
HSP70 positive tumor cells do secrete HSP70 into the extracel-
lular milieu it is expected that soluble HSP70 levels might serve
as a useful biomarker for different tumor entities. Elevated HSP70
serum levels have been found in cardiovascular, inflammatory and
pregnancy-related diseases. In this study, we could show quantita-
tive differences in soluble HSP70 levels in inflammation, cirrhosis,
and cancer. Since the highest amount of HSP70 is actively secreted
by tumor cells and not from inflamed and virally infected tissues,
soluble HSP70 levels might provide a measure to determine the
mass of viable tumor cells in patients (24).
CONCLUSION
In the present study, the prognostic value of extracellular HSP70
was determined in the serum of patients with liver diseases such
as CH, LC, and HCC. HSP70 serum levels were found to be signif-
icantly higher in cancer patients compared to healthy individuals,
patients without liver diseases and patients with an inflammation
of the liver. Our data encourage us to hypothesize that serum
HSP70 might be a useful biomarker to differentiate HCC from
other liver diseases.
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